Keywords: roche, mabthera, oked, uk, first-line, use, nhl

Roche's MabThera OKed in UK for first-line use in NHL

Article | 20 September 2004

Print This

Roche's MabThera (Rituxan; rituximab) has been granted a UK licensefor use as a first-line treatment for indolent non-Hodgkin's lymphoma in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in